Status:

RECRUITING

Arcuate Incisions With Light Adjustable Lens for Astigmatism Correction in Lens Surgery

Lead Sponsor:

Center For Sight

Collaborating Sponsors:

LensAR Incorporated

Conditions:

Astigmatism

Eligibility:

All Genders

21+ years

Phase:

PHASE4

Brief Summary

This study aims to evaluate the safety and effectiveness of femtosecond laser arcuate corneal relaxing incisions (AK) combined with Light Adjustable Lens (LAL) implantation for correcting pre-existing...

Eligibility Criteria

Inclusion

  • Subject must be aged ≥ 21 years at the time of eligibility visit.
  • Subject must have a vector difference of 0.50 D or less in magnitude of pre-operative anterior corneal astigmatism as measured by the Pentacam AXL and the Zeiss IOLMaster 700 (Carl Zeiss Meditec).
  • Subject must be able and willing to comply with the study examination procedures.
  • Astigmatic treatment must require paired arcs \<45mm in length.
  • Subject must be willing to complete the approved informed consent form.
  • Subject must have elected to undergo lens extraction and Light Adjustable Lens (LAL) implantation.
  • Subject must be willing and able to return for scheduled pre-op and follow-up examinations.
  • Subject must have central 7 mm of clear cornea without vascularization.

Exclusion

  • Subject who has undergone previous corneal or intraocular surgery in the eye to be treated.
  • Subject with a history, signs or symptoms of ocular disease or atypical findings that would be contraindicated under standard of care for lens extraction surgery.
  • Subject with neuro-ophthalmic disease.
  • Diabetic or hypertensive subject with clinical evidence of retinal pathology that the investigator believes will significantly affect visual outcomes.
  • Subject with macular degenerative pathology identified at the preoperative visit that the investigator believes will significantly affect visual outcomes.
  • Subject with a history of steroid-responsive rise in intraocular pressure (IOP), preoperative IOP \>25 mmHg, or uncontrolled glaucoma in either eye.
  • Subject with known lens/zonular instability.
  • Subject who cannot achieve dilated pupillary diameter \> 6 mm.
  • Subject with abnormal corneal topography, including evidence of forme fruste keratoconus, keratoconus or pellucid marginal degeneration.
  • Subject with posterior segment disease or degeneration.
  • Subject with corneal disease or pathology that precludes an adequate view for imaging or transmission of laser wavelength of light.
  • Subject with known sensitivity to planned perioperative standard of care medications.
  • Subject participating in any other ophthalmic drug or device clinical trial during the time of this clinical assessment.
  • Subject with known sensitivity to planned assessment concomitant medications.
  • Subjects with severe dry eye syndrome (DES) or history of ocular inflammation that may impact visual outcomes.
  • Subject with irregular astigmatism in the eye to be treated.

Key Trial Info

Start Date :

September 2 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 2 2026

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT07140653

Start Date

September 2 2025

End Date

September 2 2026

Last Update

December 22 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Center For Sight

Venice, Florida, United States, 34285

2

Carolina Eyecare Physicians

Mt. Pleasant, South Carolina, United States, 29464